Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.[8][9]
It is an inhibitor of vascular endothelial growth factor (VEGF).[10][11]
^"Yesafili: Pending EC decision". European Medicines Agency. 21 July 2023. Archived from the original on 2 October 2023. Retrieved 2 October 2023.
^"Yesafili Product information". Union Register of medicinal products. 19 September 2023. Archived from the original on 2 October 2023. Retrieved 2 October 2023.
^"Ziv-aflibercept (Zaltrap) Use During Pregnancy". Drugs.com. 25 December 2019. Archived from the original on 29 November 2020. Retrieved 12 March 2020.
^"Regulatory Decision Summary for Eylea HD". Drug and Health Products Portal. 2 February 2024. Retrieved 2 April 2024.
^Cite error: The named reference Eylea FDA label was invoked but never defined (see the help page).
^Cite error: The named reference Zaltrap FDA label was invoked but never defined (see the help page).
^"Eylea HD- aflibercept injection, solution". DailyMed. 18 August 2023. Archived from the original on 29 August 2023. Retrieved 28 August 2023.
^ ab"Eylea EPAR". European Medicines Agency (EMA). 9 July 2019. Archived from the original on 9 November 2020. Retrieved 12 March 2020.
^"Zaltrap EPAR". European Medicines Agency (EMA). 12 November 2019. Archived from the original on 11 November 2020. Retrieved 12 March 2020.
^Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ (September 2008). "The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset". Endocrinology. 149 (9): 4413–20. doi:10.1210/en.2008-0325. PMID 18499749. Archived from the original on 8 December 2019. Retrieved 3 July 2008.
^Duncan WC, van den Driesche S, Fraser HM (July 2008). "Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxia-inducible factor-1alpha in the follicle and corpus luteum". Endocrinology. 149 (7): 3313–20. doi:10.1210/en.2007-1649. PMID 18388198.
Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It...
degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to...
Schleifer and scientist George Yancopoulos in 1988. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is...
biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, which was then in Phase I clinical trials. Aventis invested $45 million...
cycle. FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the...
against aflibercept. Both studies reached its primary endpoints and showed that faricimab given at up to every 16 weeks was non-inferior to aflibercept administered...
the macula – benefit most from eye injections of anti-VEGF therapies aflibercept, bevacizumab, or ranibizumab. There is no widely accepted dosing schedule...
Bonomini M (2020). "Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations"...
membrane and to reduce formation of Drusen, is in preparation. Ranibizumab, aflibercept, brolucizumab, and faricimab are approved VEGF inhibitors for the treatment...
by diabetes and/or retinal vein occlusion. On July 29, 2014, Eylea (aflibercept), an intravitreal injection produced by Regeneron Pharmaceuticals Inc...
degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept. A 2023 systematic review update found that while ranibizumab and bevacizumab...
(2016). "Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept". International Journal of Retina and Vitreous...
development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. In November 2022, Alvogen and a former...
Global Information
(what is this?) (verify)